Paris/ Jacksonville, 4 November 2021. – The space tech company Redwire acquired the biotech company Techshot, specialized on microgravity, bioprinting, and on-orbit manufacturing for commercial space-based research and development.
This acquisition aligns with Redwire’s growth strategy to leverage strategic investments to scale in-space manufacturing in LEO which will directly impact the sustainability of future human spaceflight and deliver optimized products for Earth-based industries, the company which is listed at the New York Stock Exchange (NYSE: RDW) said.
Redwire did not disclose the financial details of the acquisition.
Techshot is at the forefront, since 1988, of biological and physical-science research in space, Redwire said. It has developed more than a dozen payloads – four of which currently are operating on the International Space Station (ISS).
The company’s key products include the 3D BioFabrication Facility: the “first American system capable of manufacturing human tissue in microgravity”, Redwire says.
Techshot’s development pipeline includes a new payload for 3D printing metal and electronic components and devices for manufacturing pharmaceuticals and large quantities of human cells for bioprinting and cell therapies. Beyond operating its own devices, Techshot also manages research in NASA’s space station furnaces and the Advanced Plant Habitat.
Techshot’s customers include Eli Lilly and Company, AstraZeneca, UCLA, MIT, and the Geneva Foundation. The company is based in Floyd County, Indiana.